title: Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.
abstract: The clinical diagnosis of neurodegenerative disorders can be supported by soluble biomarkers in cerebrospinal fluid (CSF), such as tau protein, phospho-tau, and amyloid-beta peptides. In particular, increased CSF levels of phospho-tau in Alzheimer's disease appear to reflect disease specific pathological processes. We report here evidence for the presence of soluble MAP-kinase ERK1/2 in a small set of human CSF samples from patients with Alzheimer's disease, frontotemporal degeneration, and mild cognitive impairment. The level of total ERK1/2 in CSF as measured by electrochemiluminescent assay was correlated with that of total tau and phospho-tau. A small fraction of ERK1/2 in a pooled CSF sample was found to be in the doubly phosphorylated (activated) state. Our findings suggest that i) MAP kinase ERK1/2 is apparently released under neurodegenerative conditions in parallel with tau and phospho-tau and ii) in the future, it might be possible to find in CSF samples evidence for disease related alterations in brain kinase signaling pathways by use of highly sensitive and activation-state specific anti-kinase antibodies.
authors.affiliation: Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany. hans.klafki@uni-due.de
authors.forename: Hans-Wolfgang
authors.initials: HW
authors.lastname: Klafki
authors.forename: Piotr
authors.initials: P
authors.lastname: Lewczuk
authors.forename: Heike
authors.initials: H
authors.lastname: Kamrowski-Kruck
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Maler
authors.forename: Katharina
authors.initials: K
authors.lastname: Müller
authors.forename: Oliver
authors.initials: O
authors.lastname: Peters
authors.forename: Isabella
authors.initials: I
authors.lastname: Heuser
authors.forename: Frank
authors.initials: F
authors.lastname: Jessen
authors.forename: Julius
authors.initials: J
authors.lastname: Popp
authors.forename: Lutz
authors.initials: L
authors.lastname: Frölich
authors.forename: Stefanie
authors.initials: S
authors.lastname: Wolf
authors.forename: Berit
authors.initials: B
authors.lastname: Prinz
authors.forename: Christian
authors.initials: C
authors.lastname: Luckhaus
authors.forename: Johannes
authors.initials: J
authors.lastname: Schröder
authors.forename: Johannes
authors.initials: J
authors.lastname: Pantel
authors.forename: Hermann-Josef
authors.initials: HJ
authors.lastname: Gertz
authors.forename: Heike
authors.initials: H
authors.lastname: Kölsch
authors.forename: Bernhard W
authors.initials: BW
authors.lastname: Müller
authors.forename: Hermann
authors.initials: H
authors.lastname: Esselmann
authors.forename: Mirko
authors.initials: M
authors.lastname: Bibl
authors.forename: Johannes
authors.initials: J
authors.lastname: Kornhuber
authors.forename: Jens
authors.initials: J
authors.lastname: Wiltfang
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000235:genetics / Q000473:pathology; D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D048049:Extracellular Signal-Regulated MAP Kinases / Q000134:cerebrospinal fluid / Q000235:genetics; D005260:Female; D057174:Frontotemporal Lobar Degeneration / Q000134:cerebrospinal fluid / Q000235:genetics / Q000473:pathology; D006801:Humans; D047468:Immunoprecipitation; D008297:Male; D048052:Mitogen-Activated Protein Kinase 3 / Q000134:cerebrospinal fluid* / Q000235:genetics*; D012720:Severity of Illness Index; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D016875:tau Proteins; D048049:Extracellular Signal-Regulated MAP Kinases; D048052:Mitogen-Activated Protein Kinase 3